Kronos Bio Inc
(NAS:KRON)
$
0.94865
-0.06135 (-6.07%)
Market Cap: 56.72 Mil
Enterprise Value: -63.81 Mil
PE Ratio: 0
PB Ratio: 0.41
GF Score: 32/100 - Kronos Bio Inc Phase 1/2 KB-0742 Data Update Call TranscriptOct 13, 2023
- Kronos Bio Inc Annual Shareholders Meeting TranscriptJun 22, 2023
- Kronos Bio Inc at Goldman Sachs Healthcare Conference TranscriptJun 15, 2023
- Kronos Bio Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Kronos Bio Inc at Cowen Health Care Conference TranscriptMar 07, 2023
- Kronos Bio Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptDec 01, 2022
- Kronos Bio Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Kronos Bio Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Kronos Bio Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- Kronos Bio Inc Annual Shareholders Meeting TranscriptJun 22, 2021
- Kronos Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Kronos Bio Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
Kronos Bio Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022 / 06:00PM GMT
Release Date Price:
$1.84
(-3.16%)
Umer Raffat
Evercore ISI - Analyst
Excellent. Thank you guys for joining us. Pleasure to have Kronos management join us. Many of you may obviously know and remember Norbert over the years discussing many things at Gilead. But today, this is about a new platform and new molecules. So there's a lot to discuss.
Let me turn over to you, Norbert.
Norbert Bischofberger
Kronos Bio, Inc. - President & CEO
Yes. Umer, thank you, and Evercore, for having us. It's a great pleasure to participate in this fireside chat.
Questions & Answers
Umer Raffat
Evercore ISI - Analyst
Outstanding. So Norbert, there's obviously two key programs, and we're going to jump right in. And there's newer stuff which is approaching IND enabling as well. Where do you guys get the most questions? And which one has the first, perhaps, upcoming data readout? Maybe we should start there.
Norbert Bischofberger
Kronos Bio, Inc. - President & CEO
The two programs -- the two
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)